Lava Therapeutics Company
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Technology:
Atrificial Vectors and Immune Cells
Industry:
Atrificial Vectors and Immune Cells
Headquarters:
Utrecht, Utrecht, The Netherlands
Founded Date:
2016-01-01
Employees Number:
51-100
Funding Status:
IPO
Investors Number:
9
Total Funding:
85000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2020-09-17
Last Funding Type:
Series C
Register and Claim Ownership